index: hide

#### PD-L1 ≥1%
- First-line therapy*
  - Pembrolizumab {'27718847},{'27745820},{'30955977}
  - (Carboplatin or cisplatin)/pemetrexed/pembrolizumab (non-squamous) {'29658856}
  - Carboplatin/paclitaxel/bevacizumab/atezolizumab (nonsquamous) {'29863955}
  - (Carboplatin or cisplatin)/(paclitaxel or albumin-bound paclitaxel)/pembrolizumab (squamous) {'30280635}

\* Continuation maintenance refers to the use of at least one of the agents given in first line, beyond 4–6 cycles, in the absence of disease progression.